Premium
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the F rench Prognostic Scoring System in azacitidine‐treated patients with myelodysplastic syndromes
Author(s) -
Zeidan Amer M.,
Lee JuWhei,
Prebet Thomas,
Greenberg Peter,
Sun Zhuoxin,
Juckett Mark,
Smith Mitchell R.,
Paietta Elisabeth,
Gabrilove Janice,
Erba Harry P.,
Tallman Martin S.,
Gore Steven D.
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12884
Subject(s) - azacitidine , international prognostic scoring system , myelodysplastic syndromes , medicine , oncology , cohort , gastroenterology , dna methylation , biology , bone marrow , biochemistry , gene expression , gene
Summary The revised International Prognostic Scoring System ( IPSS ‐R) was developed in a cohort of untreated myelodysplastic syndromes ( MDS ) patients. A F rench Prognostic Scoring System ( FPSS ) was recently reported to identify differential survival among azacitidine‐treated patients with high‐risk MDS . We applied the FPSS and IPSS ‐R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival ( OS ; median OS , FPSS : 9·7, 14·7, and 25·3 months, P = 0·018; IPSS ‐R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS ‐R in azacitidine‐treated patients.